Zhejiang Hisun Pharmaceutical Co.,Ltd.(600267),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

600267 Zhejiang Hisun Pharmaceutical Co.,Ltd.

Closed 04-14 15:00:00

10.35

+0.12

+1.17%

High10.36	Low10.17	Vol10.41M
Open10.24	D1 Closing10.23	Amplitude1.86%
Mkt Cap12.41B	Tradable Cap12.41B	Total Shares1.20B
T/O107.00M	T/O Rate0.87%	Tradable Shares1.20B
P/B1.44	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"600267","market":"SH","secType":"STK","nameCN":"Zhejiang Hisun Pharmaceutical Co.,Ltd.","latestPrice":10.35,"timestamp":1776150000000,"preClose":10.23,"halted":0,"volume":10409457,"delay":0,"changeRate":0.0117,"floatShares":1199000000,"shares":1199000000,"eps":0.4007,"marketStatus":"Closed","change":0.12,"latestTime":"04-14 15:00:00","open":10.24,"high":10.36,"low":10.17,"amount":107000000,"amplitude":0.0186,"askPrice":10.35,"askSize":294,"bidPrice":10.34,"bidSize":1997,"shortable":0,"etf":0,"ttmEps":0.4007,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1776216600000},"marketStatusCode":5,"adr":0,"adjPreClose":10.23,"symbolType":"stock","openAndCloseTimeList":[[1776130200000,1776137400000],[1776142800000,1776150000000]],"highLimit":11.25,"lowLimit":9.21,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1198761196,"isCdr":false,"pbRate":1.44,"roa":"--","peRate":25.829798,"roe":"6.41%","epsLYR":0.46,"committee":0.200079,"marketValue":12407000000,"turnoverRate":0.0087,"status":0,"floatMarketCap":12407000000},"requestUrl":"/m/hq/s/600267/tweets","defaultTab":"tweets","newsList":[{"id":"1197239794","title":"Hisun Pharma Reports 2025 Earnings with Net Profit Attributable to Shareholders of 541 Million Yuan, Down 10.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=1197239794","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197239794?lang=en_us&edition=fundamental","pubTime":"2026-04-07 20:20","pubTimestamp":1775564423,"startTime":"0","endTime":"0","summary":"Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SH) has released its annual report for 2025. During the reporting period, the company achieved revenue of 105.5 billion yuan, representing a...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK0239","BK0028","600267","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622848880","title":"Zhejiang Hisun Pharmaceutical Subsidiary Gets Supplementary Drug Approval for Anti-Leukemia Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2622848880","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622848880?lang=en_us&edition=fundamental","pubTime":"2026-03-27 14:41","pubTimestamp":1774593687,"startTime":"0","endTime":"0","summary":"China's drug regulator granted Zhejiang Hisun Pharmaceutical  subsidiary Hanhui Pharmaceutical a supplementary drug approval for its Idarubicin Hydrochloride Injection, according to a Friday filing with the Shanghai bourse.The injection will help induce remission of treatment-nave, as well as relapsed and refractory acute non-lymphocytic leukemia in adults.As stated in the filing, it also serves as a treatment for acute lymphoblastic leukemia.Shares rose 4% during afternoon trading on Monday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","BK0060","BK0028","600267","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620942965","title":"China Approves Hisun Subsidiary's Clinical Trial for High Cholesterol Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2620942965","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620942965?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:23","pubTimestamp":1773746581,"startTime":"0","endTime":"0","summary":"China's drug regulator approved Zhejiang Hisun Pharmaceutical  subsidiary Hanhui Pharmaceutical's clinical trial for its Hybomimab atorvastatin calcium tablets, according to a Tuesday disclosure to the Shanghai bourse.The drug is indicated for patients with high cholesterol levels whose low-density lipoprotein levels could not be achieved with solo statin therapy, the filing said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0060","600267","BK0188","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173944726","title":"Hisun Pharma Receives Clinical Trial Approval for Hybomet-Atorvastatin Calcium Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=1173944726","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173944726?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:55","pubTimestamp":1773662155,"startTime":"0","endTime":"0","summary":"Zhejiang Hisun Pharmaceutical Co.,Ltd. (600267.SH) announced that its wholly-owned subsidiary, Hisun Pharmaceutical Co., Ltd., has received a drug clinical trial approval notice from the National...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","600267","BK0239","BK0188","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616631346","title":"Zhejiang Hisun Pharmaceutical Secures Approval for Canine Antifungal Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2616631346","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616631346?lang=en_us&edition=fundamental","pubTime":"2026-03-03 18:34","pubTimestamp":1772534050,"startTime":"0","endTime":"0","summary":"Zhejiang Hisun Pharmaceutical  unit Hisun Animal Health obtained veterinary drug approval from China's agriculture ministry for terbinafine hydrochloride tablets.The drug, with brand name Fenlishu, is indicated for canine skin infections caused by Microsporum canis, according to a Tuesday filing with the Shanghai bourse.The approval is valid until Feb. 13, 2031.Shares of the company were down 2% in recent trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","BK0028","BK0188","BK0060","600267"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121659246","title":"Subsidiary of Zhejiang Hisun Pharmaceutical Obtains Veterinary Drug Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1121659246","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121659246?lang=en_us&edition=fundamental","pubTime":"2026-03-02 18:18","pubTimestamp":1772446713,"startTime":"0","endTime":"0","summary":"Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SH) has announced that its subsidiary, Zhejiang Hisun Animal Health Co., Ltd., recently received approval from the Ministry of Agriculture and Rural...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","BK0060","BK0188","600267","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100623066","title":"Hisun Pharma's Ticagrelor Active Ingredient Receives European CEP Certification","url":"https://stock-news.laohu8.com/highlight/detail?id=1100623066","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100623066?lang=en_us&edition=fundamental","pubTime":"2026-02-24 17:13","pubTimestamp":1771924407,"startTime":"0","endTime":"0","summary":"Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SH) announced that it has recently obtained a Certificate of Suitability to the Monograph of the European Pharmacopoeia (CEP) for its ticagrelor active...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","600267","BK0188","BK0028","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198170644","title":"Hisun Pharmaceutical: No Share Buybacks Conducted in January","url":"https://stock-news.laohu8.com/highlight/detail?id=1198170644","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198170644?lang=en_us&edition=fundamental","pubTime":"2026-02-02 21:31","pubTimestamp":1770039082,"startTime":"0","endTime":"0","summary":"Zhejiang Hisun Pharmaceutical Co., Ltd. announced on February 2nd that the company did not repurchase any of its shares during January 2026.","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0060","BK0028","BK0188","BK0239","600267"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144886943","title":"Turning the Page on Historical Issues: Hisun Pharma's New Management Pushes Forward with Strategic Adjustments","url":"https://stock-news.laohu8.com/highlight/detail?id=1144886943","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144886943?lang=en_us&edition=fundamental","pubTime":"2026-01-17 11:10","pubTimestamp":1768619440,"startTime":"0","endTime":"0","summary":"On January 16, Zhejiang Hisun Pharmaceutical Co.,Ltd. announced that it had received a warning letter issued by the Zhejiang Securities Regulatory Bureau. The letter pointed out that the company had...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0060","BK0028","600267","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186342086","title":"Financial Information Found Inauthentic and Inaccurate: Hisun Pharma Receives Public Censure","url":"https://stock-news.laohu8.com/highlight/detail?id=1186342086","media":"Deep News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186342086?lang=en_us&edition=fundamental","pubTime":"2026-01-17 10:00","pubTimestamp":1768615247,"startTime":"0","endTime":"0","summary":"On January 16, 2026, the Shanghai Stock Exchange issued a public censure against Zhejiang Hisun Pharmaceutical Co.,Ltd. (600267.SH) and six of its senior executives. The disciplinary action was taken...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","BK0188","600267","BK0060","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601847461","title":"Zhejiang Hisun Pharmaceutical Investee Company Applies for Hong Kong Listing","url":"https://stock-news.laohu8.com/highlight/detail?id=2601847461","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601847461?lang=en_us&edition=fundamental","pubTime":"2026-01-07 09:48","pubTimestamp":1767750520,"startTime":"0","endTime":"0","summary":"Zhejiang Hisun Pharmaceutical  said 39.62%-owned Zhejiang Bioray Biopharmaceutical on Jan. 6 submitted an application to list H shares on the Hong Kong Stock Exchange.Zhejiang Bioray Biopharmaceutical is an immunotherapy-focused biopharmaceutical company with integrated research and development, manufacturing, and commercialization capabilities, according to a Wednesday filing with the Shanghai bourse.The offering is subject to approvals of the China Securities Regulatory Commission, the Hong Kong Securities and Futures Commission and the Hong Kong bourse.Shares of Hisun Pharma rose nearly 3% in Shanghai trading early Wednesday morning.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0060","600267","BK0239","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2600104267","title":"BRIEF-Zhejiang Hisun Pharmaceutical's Shareholder Plans To Sell Stake In Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2600104267","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600104267?lang=en_us&edition=fundamental","pubTime":"2026-01-04 16:27","pubTimestamp":1767515244,"startTime":"0","endTime":"0","summary":"BRIEF-Zhejiang Hisun Pharmaceutical's Shareholder Plans To Sell Stake In CoJan 4 (Reuters) - Zhejiang Hisun Pharmaceutical Co Ltd 600267.SS:SAYS SHAREHOLDER PLANS TO SELL 6.1% STAKE IN COSource textFurther company coverage: 600267.SS (Reporting by Beijing Newsroom) ((Shi.Bu@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260104:nL4N3Y5025:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0060","600267","BK0188","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2600044367","title":"Zhejiang Hisun Pharmaceutical  Says Shareholder Plans to Sell 6.1% Stake in Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2600044367","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600044367?lang=en_us&edition=fundamental","pubTime":"2026-01-04 16:27","pubTimestamp":1767515244,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260104:nL4N3Y5025:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","600267","BK0188","BK0060","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2593006426","title":"Hisun Pharmaceutical Gets China Approval for Kidney Cancer Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2593006426","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593006426?lang=en_us&edition=fundamental","pubTime":"2025-12-24 13:01","pubTimestamp":1766552486,"startTime":"0","endTime":"0","summary":"Chinese drug regulators approved the everolimus tablets produced by Zhejiang Hisun Pharmaceutical , according to a Wednesday disclosure to the Shanghai bourse.The drug approval is valid through Jan. 1, 2030.Everolimus is indicated for patients with kidney cancer whose prior treatments have failed.The drug is also indicated for patients with advanced pancreatic neuroendocrine tumors, and advanced non-functional gastrointestinal or pulmonary neuroendocrine tumors, among others, the filing said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0060","BK0239","600267","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2593264904","title":"Zhejiang Hisun Pharmaceutical Subsidiary Gets China Approval for Antibiotic, Swine Fever Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2593264904","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593264904?lang=en_us&edition=fundamental","pubTime":"2025-12-24 12:47","pubTimestamp":1766551676,"startTime":"0","endTime":"0","summary":"China's agriculture ministry approved the doxycycline hydrochloride tablets and classical swine fever virus vaccine produced by Zhejiang Hisun Pharmaceutical  subsidiary Zhejiang Hisun Animal Health Products.The antibiotic is indicated for infections caused by gram-positive and gram-negative bacteria, as well as mycoplasma, according to a Wednesday filing with the Shanghai bourse.Hisun's classical swine fever virus E2 protein recombinant baculovirus helps prevent the disease with an immunity period of six months.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0060","600267","BK0239","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181896611","title":"Zhejiang Hisun Pharmaceutical's Subsidiaries Obtain Veterinary Drug Approval Certificates","url":"https://stock-news.laohu8.com/highlight/detail?id=1181896611","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181896611?lang=en_us&edition=fundamental","pubTime":"2025-12-23 17:20","pubTimestamp":1766481621,"startTime":"0","endTime":"0","summary":"Zhejiang Hisun Pharmaceutical Co.,Ltd. (600267.SH) announced that its subsidiaries, Zhejiang Hisun Animal Health Co., Ltd. (\"Hisun Animal Health\") and Yunnan Biological Pharmaceutical Co., Ltd....","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","BK0188","600267","BK0060","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2593468918","title":"Zhejiang Hisun Pharmaceutical Gets US FDA Approval for Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2593468918","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593468918?lang=en_us&edition=fundamental","pubTime":"2025-12-23 11:02","pubTimestamp":1766458935,"startTime":"0","endTime":"0","summary":"Zhejiang Hisun Pharmaceutical  obtained the approval of the U.S. Food and Drug Administration to start clinical trials for its HS387 tabletsThe drug is intended to treat advanced solid tumors, including serous ovarian cancer and non-small cell lung cancer, according to a Tuesday filing with the Shanghai bourse.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0188","BK0239","BK0028","BK0060","600267"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186022091","title":"Zhejiang Hisun Pharmaceutical (600267.SH): HS387 Tablets Receive FDA Approval for Clinical Trials in the U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=1186022091","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186022091?lang=en_us&edition=fundamental","pubTime":"2025-12-22 17:08","pubTimestamp":1766394527,"startTime":"0","endTime":"0","summary":"Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SH) announced that it recently received notification from the U.S. Food and Drug Administration (FDA) approving the clinical trial application for its...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0060","BK0028","600267","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2592267158","title":"Zhejiang Hisun Pharmaceutical Gets China Approval for Anti-Allergy Drug for Dogs","url":"https://stock-news.laohu8.com/highlight/detail?id=2592267158","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592267158?lang=en_us&edition=fundamental","pubTime":"2025-12-19 14:01","pubTimestamp":1766124109,"startTime":"0","endTime":"0","summary":"Chinese agriculture regulators approved Zhejiang Hisun Pharmaceutical's  methylprednisolone drug registration for dogs, according to a Friday disclosure to the Shanghai bourse.The drug is indicated for inflammation and allergies in dogs, including allergic or nonspecific dermatitis, or immune-mediated conditions, the filing said.Shares rose 2% during afternoon trading on Friday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","600267","BK0188","BK0028","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190973583","title":"Zhejiang Hisun Pharmaceutical's Subsidiary Obtains New Veterinary Drug Registration Certificate","url":"https://stock-news.laohu8.com/highlight/detail?id=1190973583","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190973583?lang=en_us&edition=fundamental","pubTime":"2025-12-18 17:08","pubTimestamp":1766048907,"startTime":"0","endTime":"0","summary":"Zhejiang Hisun Pharmaceutical Co.,Ltd. (600267.SH) announced that its subsidiary, Zhejiang Hisun Animal Health Products Co., Ltd., recently received the New Veterinary Drug Registration Certificate...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","BK0060","600267","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2000-07-25","address":"浙江省台州市椒江区外沙路46号","stockEarnings":[{"period":"1week","weight":-0.0285},{"period":"1month","weight":-0.0303},{"period":"3month","weight":-0.034},{"period":"6month","weight":-0.0229},{"period":"1year","weight":0.1636},{"period":"ytd","weight":0.0344}],"companyName":"浙江海正药业股份有限公司","boardCode":"AI0027","perCapita":"25145股","boardName":"医药制造业","registeredCapital":"119876万元","compareEarnings":[{"period":"1week","weight":0.028},{"period":"1month","weight":-0.0261},{"period":"3month","weight":-0.0363},{"period":"6month","weight":0.0195},{"period":"1year","weight":0.2317},{"period":"ytd","weight":0.005}],"survey":"　　浙江海正药业股份有限公司的主营业务是化学原料药和制剂的研发、生产和销售业务。公司的主要产品是抗肿瘤药、抗感染药、心血管药、抗寄生虫药及兽药、内分泌药、其他药品、医药商业、CMO/CDMO/CRO业务、其他。公司入选中国医药工业信息中心“2025年中国医药研发产品线工业企业优秀案例”、2024年度中国医药工业百强榜、人民网“2025人民企业社会责任案例”；获得第90届药交会“首届创新药上市解决方案大赛”综合实力奖，入选2025中国制药工业TOP101榜单；荣膺EcoVadis铜牌认证，可持续发展实践获国际认可；子公司瀚晖制药荣获“浙江省先进级智能工厂”认定；澐生合成荣获BRCGSA级认证，打造合成生物学质量新标杆。","serverTime":1776156942779,"listedPrice":11.83,"stockholders":"47673人(较上一季度减少6.51%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Zhejiang Hisun Pharmaceutical Co.,Ltd.(600267),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Zhejiang Hisun Pharmaceutical Co.,Ltd.(600267) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Zhejiang Hisun Pharmaceutical Co.,Ltd.,600267,Zhejiang Hisun Pharmaceutical Co.,Ltd.股票,Zhejiang Hisun Pharmaceutical Co.,Ltd.股票老虎,Zhejiang Hisun Pharmaceutical Co.,Ltd.股票老虎国际,Zhejiang Hisun Pharmaceutical Co.,Ltd.行情,Zhejiang Hisun Pharmaceutical Co.,Ltd.股票行情,Zhejiang Hisun Pharmaceutical Co.,Ltd.股价,Zhejiang Hisun Pharmaceutical Co.,Ltd.股市,Zhejiang Hisun Pharmaceutical Co.,Ltd.股票价格,Zhejiang Hisun Pharmaceutical Co.,Ltd.股票交易,Zhejiang Hisun Pharmaceutical Co.,Ltd.股票购买,Zhejiang Hisun Pharmaceutical Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Zhejiang Hisun Pharmaceutical Co.,Ltd.(600267),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Zhejiang Hisun Pharmaceutical Co.,Ltd.(600267) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction